Analyst Paul Matteis of Stifel Nicolaus maintained a Hold rating on Biogen, reducing the price target to $144.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Paul Matteis has given his Hold rating due to a combination of factors related to Biogen’s current focus and future potential. While Biogen’s development efforts in lupus present a meaningful long-term opportunity, the complexity and heterogeneity of lupus as a disease pose significant challenges. The absence of near-term clinical catalysts, with key data readouts for lupus treatments not expected until 2026 and beyond, limits the immediate impact on Biogen’s stock narrative.
Additionally, investors are currently more focused on Biogen’s commercial execution of lecanemab and the outcomes of Alzheimer’s disease trials, which are anticipated in the near future. The lupus program, although promising, involves clinical risks and a profit-sharing agreement with UCB, which could limit its upside potential. These elements contribute to a cautious outlook, justifying the Hold rating until more definitive results are available.
In another report released on September 2, Morgan Stanley also maintained a Hold rating on the stock with a $144.00 price target.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BIIB in relation to earlier this year.